

# Chapter 169

## Cryoglobulinemia and Cryofibrinogenemia

Holger Schmid & Gerald S. Braun

### REFERENCES

1. Lerner AB, Watson CJ: Studies of cryoglobulins. II. The spontaneous precipitation of protein from serum at 5°C in various disease states. *Am J Med Sci* **214**:416, 1947
2. Brouet JC et al: Biologic and clinical significance of cryoglobulins. A report of 86 cases. *Am J Med* **57**:775-788, 1974
3. Lunel F et al: Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. *Gastroenterology* **106**:1291-1300, 1994
4. Pawlotsky JM et al: Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. *Hepatology* **19**:841-848, 1994
5. Santagostino E et al: High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C. *Blood* **92**:516-519, 1998
6. Lapinski TW et al: Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. *Liver Int* **29**:1158-1161, 2009
7. Cacoub P et al: Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. *Arthritis Rheum* **42**:2204-2212, 1999
8. Cacoub P et al: Cryoglobulinemia vasculitis. *Curr Opin Rheumatol* **14**:29-35, 2002
9. Fiorentino DF: Cutaneous vasculitis. *J Am Acad Dermatol* **48**:311-340, 2003
10. Armstrong GL et al: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med* **144**:705-714, 2006
11. Lauer GM, Walker BD: Hepatitis C virus infection. *N Engl J Med* **345**:41-52, 2001
12. Ferri C: Mixed cryoglobulinemia. *Orphanet J Rare Dis* **3**:25, 2008
13. Wintrobe M, Buell M: Hyperproteinemia associated with multiple myeloma. With report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud's disease. *Bull Johns Hopkins Hosp* **52**:156-165, 1933
14. Zinneman HH: Cryoglobulins and pyroglobulins. *Pathobiol Annu* **10**:83-104, 1980
15. Tissot JD et al: Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. *J Immunol Methods* **173**:63-75, 1994
16. Cacoub P et al: Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. *Arthritis Rheum* **44**:2118-2124, 2001
17. Sebastiani GD et al: Association of extrahepatic manifestations with HLA class II alleles and with virus genotype in HCV infected patients. *J Biol Regul Homeost Agents* **19**:17-22, 2005
18. Charles ED, Dustin LB: Hepatitis C virus-induced cryoglobulinemia. *Kidney Int* **76**:818-824, 2009
19. Monti G et al: Cryoglobulinaemias: A multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. *QJM* **88**:115-126, 1995
20. Saadoun D et al: Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. *Arch Intern Med* **166**:2101-2108, 2006
21. Sene D et al: Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. *J Rheumatol* **31**:2199-2206, 2004
22. Vallat L et al: Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. *Arthritis Rheum* **50**:3668-3678, 2004
23. Levo Y et al: Association between hepatitis B virus and essential mixed cryoglobulinemia. *N Engl J Med* **296**:1501-1504, 1977
24. Dimitrakopoulos AN et al: Mixed cryoglobulinemia in HIV-1 infection: The role of HIV-1. *Ann Intern Med* **130**:226-230, 1999
25. Chiche L et al: Mixed cryoglobulinemia: A role for parvovirus b19 infection. *Clin Infect Dis* **50**:1074-1075, 2010

26. Ramos-Casals M et al: Cutaneous vasculitis in primary Sjogren syndrome: Classification and clinical significance of 52 patients. *Medicine (Baltimore)* **83**:96-106, 2004
27. Ramos-Casals M et al: Cryoglobulinemia in primary Sjogren's syndrome: prevalence and clinical characteristics in a series of 115 patients. *Semin Arthritis Rheum* **28**:200-205, 1998
28. Garcia-Carrasco M et al: Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. *Semin Arthritis Rheum* **30**:366-373, 2001
29. Ferri C et al: Mixed cryoglobulinemia: Demographic, clinical, and serologic features and survival in 231 patients. *Semin Arthritis Rheum* **33**:355-374, 2004
30. Perico N et al: Hepatitis C infection and chronic renal diseases. *Clin J Am Soc Nephrol* **4**:207-220, 2009
31. Hent RC et al: Delayed onset of membranoproliferative glomerulonephritis in a patient with type I cryoglobulinaemia. *Nephrol Dial Transplant* **12**:2155-2158, 1997
32. Kamar N, Rostaing L, Alric L: Treatment of hepatitis C-virus-related glomerulonephritis. *Kidney Int* **69**:436-439, 2006
33. Johnson RJ et al: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. *N Engl J Med* **328**:465-470, 1993.
34. Johnson RJ, Feehally J. *Comprehensive Clinical Nephrology* Edinburgh, New York, Mosby, 2003
35. Fornasieri A et al: High binding of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular fibronectin: A mechanism for induction of in situ immune complex glomerulonephritis? *Am J Kidney Dis* **27**:476-483, 1996
36. Roccatello D et al; Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. *Am J Kidney Dis* **49**:69-82, 2007
37. Fabrizi F et al: Kidney and liver involvement in cryoglobulinemia. *Semin Nephrol* **22**:309-318, 2002
38. Beddhu S, Bastacky S, Johnson JP: The clinical and morphologic spectrum of renal cryoglobulinemia. *Medicine (Baltimore)* **81**:398-409, 2002
39. Antonelli A et al: Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. *Rheumatology (Oxford)* **43**:238-240, 2004
40. Vitali C et al: Hypercomplementaemia as a marker of the evolution from benign to malignant B cell proliferation in patients with type II mixed cryoglobulinaemia. *Br J Rheumatol* **33**:791-792, 1994
41. Antonelli A et al: Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. *Arthritis Rheum* **60**:3841-3847, 2009
42. Antonelli A et al: Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. *J Rheumatol* **37**:91-97, 2009
43. Sansonno D et al: Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. *Blood* **112**:1620-1627, 2008
44. Monti G, Saccardo F: Emergency in cryoglobulinemic syndrome: What to do? *Dig Liver Dis* **39**(Suppl. 1):S112-S115, 2007
45. Della Rossa A et al: Mixed cryoglobulinemia and mortality: A review of the literature. *Clin Exp Rheumatol* **26**:S105-S108, 2008
46. Saccardo E et al: Causes of death in symptomatic cryoglobulinemia: 30 years of observation in a Department of Internal Medicine. *Dig Liver Dis* **39**(Suppl. 1):S52-S54, 2007
47. Landau DA et al: Causes and predictive factors of mortality in a cohort of patients with hepatitis c virus-related cryoglobulinemic vasculitis treated with antiviral therapy. *J Rheumatol* **37**:615-621, 2010
48. Bruchfeld A et al: Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. *Nephrol Dial Transplant* **18**:1573-1580, 2003
49. Sabry AA et al: Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. *Nephrol Dial Transplant* **17**:1924-1930, 2002
50. Gorevic PD et al: Mixed cryoglobulinemia: Clinical aspects and long-term follow-up of 40 patients. *Am J Med* **287**-308, 1980
51. Matignon M et al: Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. *Medicine (Baltimore)* **88**:341-348, 2009
52. Cacoub P et al: PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. *Arthritis Rheum* **52**:911-915, 2005
53. Saadoun D et al: Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. *Arthritis Rheum* **54**:3696-3706, 2006

54. Saadoun D et al: Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. *Ann Rheum Dis* **67**:1431-1436, 2008
55. Cacoub P et al: PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. *Arthritis Rheum* **52**:911-915, 2005
56. Cacoub P et al: Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. *Arthritis Rheum* **46**:3317-3326, 2002
57. Casato M et al: Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. *Blood* **90**:3865-3873, 1997
58. Dammacco F et al: Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: A long-term, randomized, controlled study. *Blood* **84**:3336-3343, 1994
59. Mazzaro C et al: Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: A pilot study. *J Hepatol* **42**:632-638, 2005
60. Misiani R et al: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. *N Engl J Med* **330**:751-756, 1994
61. Naarendorp M et al: Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. *J Rheumatol* **28**:2466-2473, 2001
62. Saadoun D et al: Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. *Arthritis Rheum* **54**:3696-3706, 2006
63. Zuckerman E et al: Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. *J Rheumatol* **27**:2172-2178, 2000
64. Dienstag JL, McHutchison JG: American Gastroenterological Association technical review on the management of hepatitis C. *Gastroenterology* **130**:231-264, 2006; quiz 214-217
65. Dienstag JL, McHutchison JG: American Gastroenterological Association medical position statement on the management of hepatitis C. *Gastroenterology* **130**:225-230, 2006
66. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. *Kidney Int Suppl* (109):S1-S99, 2008
67. Bruchfeld A et al: Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis. *Ther Drug Monit* **24**:701-708, 2002
68. Saadoun D et al: Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. *Curr Opin Rheumatol* **20**:23-28, 2008
69. Cacoub P et al: Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: Where do we stand? *Ann Rheum Dis* **67**:283-287, 2008
70. Sansonno D et al: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. *Blood* **101**:3818-3826, 2003
71. Garini G et al: Successful treatment of severe/active cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection by means of the sequential administration of immunosuppressive and antiviral agents. *Nephrol Dial Transplant* **21**:3333-3334, 2006
72. Saadoun D et al: Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. *Ann Rheum Dis* **67**:1431-1436, 2008
73. Sene D et al: Rituximab may form a complex with IgM kappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. *Arthritis Rheum* **60**:3848-3855, 2009
74. Landau DA et al: Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. *Arthritis Rheum* **58**:604-611, 2008
75. Saadoun D et al: Cryofibrinogenemia: new insights into clinical and pathogenic features. *Am J Med* **122**:1128-1135, 2009
76. Belizna CC et al: Outcome of essential cryofibrinogenemia in a series of 61 patients. *Rheumatology (Oxford)* **47**:205-207, 2008
77. Korst DR, Kratochvil CH: Cryofibrinogen in a case of lung neoplasm associated with thrombophlebitis migrans. *Blood* **10**:945-953, 1955
78. Blain H et al: Cryofibrinogenemia: A study of 49 patients. *Clin Exp Immunol* **120**:253-260, 2000
79. Delluc A et al: Cryofibrinogen in patients with hepatitis C virus infection. *Am J Med* **121**:624-631, 2008
80. Singh A, Gaber LW: Nephrotic syndrome and chronic renal insufficiency associated with essential cryofibrinogenemia. *Nephrol Dial Transplant* **22**:1772-1775, 2007

81. McGrath MA et al: Systemic factors contributory to retinal vein occlusion. *Arch Intern Med* **138**:216-220, 1978
82. Nash JW et al: The histopathologic spectrum of cryofibrinogenemia in four anatomic sites. Skin, lung, muscle, and kidney. *Am J Clin Pathol* **119**:114-122, 2003
83. Lee J et al: Cryofibrinogenemia in a patient with B-cell lymphoma. *Clin Lymphoma* **1**:234-237, 2000; discussion 238-9.
84. Kirsner RS et al: Stanazolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia. *J Am Acad Dermatol* **28**:71-74, 1993
85. Chartier M, Falanga V. Healing of ulcers due to cryofibrinogenemia with colchicine and high-dose pentoxifylline. *Am J Clin Dermatol* **10**:39-42, 2009
86. Euler HH et al: Monoclonal cryo-antifibrinogenemia. *Arthritis Rheum* **39**:1066-1069, 1996